This "Company Business Analysis and Segment Overview" (CBASO) is designed to provide a concise executive summary of a leading company in a particular industry and that company's applicable sector focus.

In the process, this CBASO examines the functionality of the Digene's Hybrid Capture System as it relates to improved, early detection of the human papillomavirus (HPV), which is the primary cause of cervical cancer.

In addition to its HPV testing products, Digene's diagnostic test products portfolio includes gene-based tests for the detection of chlamydia, gonorrhea, cytomegalovirus, and hepatitis B virus.